Kailera Therapeutics, Inc. (NASDAQ: KLRA) is a Healthcare company (Biotechnology) with a market capitalization of $1.6B. The Maz Rating grades it against the other companies in its sector.
Kailera Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $12.20, Kailera Therapeutics, Inc. trades at 1.5x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -102.3%, return on invested capital of -36.4% and a free cash flow yield of -20.7%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 21.84. Over the past 52 weeks the share price ranged from $9.76 to $28.23, with a beta of 0.50.
Kailera Therapeutics, Inc. does not currently pay a dividend.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.